• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.910 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,160
Open 6.910
Bid (Size) 6.800 (200)
Ask (Size) 7.200 (100)
Prev. Close 6.910
Today's Range 6.910 - 6.910
52wk Range 4.360 - 14.06
Shares Outstanding 52,700,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
Today 8:00 EDT
From Emergent BioSolutions Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
September 22, 2026
From Pomerantz LLP
Via GlobeNewswire

Performance

52-Week Range 50.9% below 52-week high
6.910
4.3652W Low 14.0652W High
1 Week 5.7% below 1-week high
6.591W Low 7.331W High

Emergent BioSolutions Inc. Common Stock (EBS) traded between $4.36 and $14.06 over the past 52 weeks and last traded at $6.91, 50.9% below its 52-week high. Over the past week it ranged between $6.59 and $7.33.

Past 12 Months
+1.5%
+8.3%
-12.4%
-20.2%
-44.8%
-24.0%
1W +$0.10
1M +$0.53
3M -$0.98
6M -$1.75
YTD -$5.60
1Y -$2.18

EBS was -24.0% over the past year, -20.2% over six months, -44.8% year to date, +1.5% in the last week.

12 Months vs Market
EBS
-24.0%
DIA
+11.4%
SPY
+16.2%
QQQ
+21.9%
IWM
+9.5%

Over the past 12 months EBS returned -24.0% versus DIA (Dow) +11.4%, SPY (S&P 500) +16.2%, QQQ (Nasdaq 100) +21.9% and IWM (Russell 2000) +9.5%.

Volume & Liquidity 0.00× 3-mo avg
Today 4,160 3-mo avg 1.2M
1W
857.5K
1M
1.1M
3M
1.2M
6M
991.5K
YTD
970.1K
1Y
987.5K

EBS most recently traded 4,160 shares against a 3-month average daily volume of 1.2M.

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
September 15, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility
September 15, 2026
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions (NYSE:EBS) Beats Q2 Estimates, but Stock Drops on NARCAN Impairment and Restructuring Costs ↗
August 05, 2026
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
September 08, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
September 03, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
September 01, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
September 01, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray
August 31, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
August 31, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
August 25, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
August 19, 2026
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 18, 2026
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
August 17, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings
News headline image
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)
August 12, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Emergent Biosolutions Q2 Earnings Call Highlights ↗
August 08, 2026
Via MarketBeat
Topics Earnings Economy
Wondering what's happening in today's after-hours session? ↗
August 05, 2026
Via Chartmill
News headline image
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
August 05, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
August 05, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
July 22, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
June 29, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
June 04, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
May 28, 2026
From Emergent BioSolutions
Via GlobeNewswire

Frequently Asked Questions

Is Emergent BioSolutions Inc. Common Stock publicly traded?
Yes, Emergent BioSolutions Inc. Common Stock is publicly traded.
What exchange does Emergent BioSolutions Inc. Common Stock trade on?
Emergent BioSolutions Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Emergent BioSolutions Inc. Common Stock?
The ticker symbol for Emergent BioSolutions Inc. Common Stock is EBS on the New York Stock Exchange
What is the current price of Emergent BioSolutions Inc. Common Stock?
The current price of Emergent BioSolutions Inc. Common Stock is 6.910
When was Emergent BioSolutions Inc. Common Stock last traded?
The last trade of Emergent BioSolutions Inc. Common Stock was at 10/14/26 07:00 PM ET
What is the market capitalization of Emergent BioSolutions Inc. Common Stock?
The market capitalization of Emergent BioSolutions Inc. Common Stock is 364.16M
How many shares of Emergent BioSolutions Inc. Common Stock are outstanding?
Emergent BioSolutions Inc. Common Stock has 364M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap